SG11202106605VA - Compounds that participate in cooperative binding and uses thereof - Google Patents
Compounds that participate in cooperative binding and uses thereofInfo
- Publication number
- SG11202106605VA SG11202106605VA SG11202106605VA SG11202106605VA SG11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA SG 11202106605V A SG11202106605V A SG 11202106605VA
- Authority
- SG
- Singapore
- Prior art keywords
- participate
- compounds
- cooperative binding
- cooperative
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783816P | 2018-12-21 | 2018-12-21 | |
| US201962894493P | 2019-08-30 | 2019-08-30 | |
| US201962930489P | 2019-11-04 | 2019-11-04 | |
| PCT/US2019/068100 WO2020132597A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106605VA true SG11202106605VA (en) | 2021-07-29 |
Family
ID=71099011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106605VA SG11202106605VA (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200197391A1 (en) |
| EP (1) | EP3897644A4 (en) |
| JP (2) | JP2022520154A (en) |
| KR (1) | KR20210116479A (en) |
| CN (1) | CN113498342A (en) |
| AU (1) | AU2019401466B2 (en) |
| BR (1) | BR112021012057A2 (en) |
| CA (1) | CA3123869A1 (en) |
| IL (2) | IL317393A (en) |
| MX (1) | MX2021007468A (en) |
| SA (1) | SA521422304B1 (en) |
| SG (1) | SG11202106605VA (en) |
| TW (1) | TW202039509A (en) |
| WO (1) | WO2020132597A1 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12019500056B1 (en) | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CA3051206A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Bicyclic compounds as allosteric shp2 inhibitors |
| KR20190110588A (en) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | Pyridine Compounds as Allosteric SHP2 Inhibitors |
| MX2020003579A (en) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors. |
| TW201927791A (en) | 2017-12-15 | 2019-07-16 | 美商銳新醫藥公司 | Polycyclic compounds as allosteric SHP2 inhibitors |
| CN114867735A (en) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | RAS inhibitors |
| CR20220241A (en) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | RAS INHIBITORS |
| CN114901366A (en) | 2019-11-04 | 2022-08-12 | 锐新医药公司 | RAS inhibitors |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| IL303419A (en) * | 2020-12-17 | 2023-08-01 | Blossomhill Therapeutics Inc | Macrocyclic compounds and their use |
| AU2022249177A1 (en) * | 2021-04-02 | 2023-10-19 | Revolution Medicines, Inc. | Methods for inhibiting ras |
| WO2022214701A1 (en) * | 2021-04-09 | 2022-10-13 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| JP2024516450A (en) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| CA3217920A1 (en) | 2021-05-05 | 2022-11-10 | Andreas BUCKL | Ras inhibitors for the treatment of cancer |
| CN118234731A (en) | 2021-05-05 | 2024-06-21 | 锐新医药公司 | RAS inhibitors |
| AU2022281343A1 (en) | 2021-05-25 | 2023-11-30 | Revolution Medicines, Inc. | Methods for inhibiting ras |
| US12280055B2 (en) | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2023015559A1 (en) * | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (en) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| JP2025500878A (en) | 2021-12-17 | 2025-01-15 | ジェンザイム・コーポレーション | PYRAZOLO-PYRAZINE COMPOUNDS AS SHP2 INHIBITORS |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN119156393A (en) * | 2022-04-25 | 2024-12-17 | 翰森生物有限责任公司 | Cyclic compound, preparation method and medical application thereof |
| EP4532503A1 (en) | 2022-06-01 | 2025-04-09 | F. Hoffmann-La Roche AG | Haloindole macrocyclic compounds for the treatment of cancer |
| KR20250022133A (en) * | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | macrocyclic RAS inhibitors |
| CN117903169A (en) * | 2022-09-19 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | A pan-KRAS inhibitor compound |
| CN119977995A (en) | 2022-09-29 | 2025-05-13 | 广州嘉越医药科技有限公司 | Macrocyclic derivatives and their use |
| CN118373832B (en) * | 2023-01-20 | 2025-01-28 | 深圳晶蛋生物医药科技有限公司 | Macrocyclic compounds, pharmaceutical compositions and applications thereof |
| EP4469164A1 (en) | 2023-02-14 | 2024-12-04 | F. Hoffmann-La Roche AG | Tricyclic compounds for the treatment of cancer |
| TW202504611A (en) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AR132338A1 (en) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | RAS INHIBITORS |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN116284045A (en) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | Chiral indole unit substituted tetrahydroisoquinoline compound and synthesis method thereof |
| CN116570599B (en) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Application and pharmaceutical composition of VS6766 combined with LY3009120 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025090809A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| AU2011214135B2 (en) * | 2010-02-09 | 2014-07-31 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| ES2907071T3 (en) * | 2011-05-19 | 2022-04-21 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Macrocyclic compounds as protein kinase inhibitors |
| AR091279A1 (en) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE |
-
2019
- 2019-12-20 BR BR112021012057-2A patent/BR112021012057A2/en unknown
- 2019-12-20 SG SG11202106605VA patent/SG11202106605VA/en unknown
- 2019-12-20 US US16/723,438 patent/US20200197391A1/en not_active Abandoned
- 2019-12-20 EP EP19901393.9A patent/EP3897644A4/en active Pending
- 2019-12-20 MX MX2021007468A patent/MX2021007468A/en unknown
- 2019-12-20 JP JP2021535755A patent/JP2022520154A/en active Pending
- 2019-12-20 KR KR1020217022312A patent/KR20210116479A/en active Pending
- 2019-12-20 IL IL317393A patent/IL317393A/en unknown
- 2019-12-20 CA CA3123869A patent/CA3123869A1/en active Pending
- 2019-12-20 AU AU2019401466A patent/AU2019401466B2/en active Active
- 2019-12-20 IL IL284210A patent/IL284210B2/en unknown
- 2019-12-20 TW TW108146857A patent/TW202039509A/en unknown
- 2019-12-20 WO PCT/US2019/068100 patent/WO2020132597A1/en active IP Right Grant
- 2019-12-20 CN CN201980092760.0A patent/CN113498342A/en active Pending
-
2021
- 2021-06-17 SA SA521422304A patent/SA521422304B1/en unknown
-
2023
- 2023-03-16 US US18/184,766 patent/US20240139185A1/en active Pending
-
2024
- 2024-11-22 JP JP2024203859A patent/JP2025037925A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3123869A1 (en) | 2020-06-25 |
| EP3897644A1 (en) | 2021-10-27 |
| JP2022520154A (en) | 2022-03-29 |
| AU2019401466A1 (en) | 2021-07-01 |
| BR112021012057A2 (en) | 2021-10-19 |
| WO2020132597A8 (en) | 2020-07-16 |
| WO2020132597A1 (en) | 2020-06-25 |
| EP3897644A4 (en) | 2022-09-07 |
| SA521422304B1 (en) | 2023-12-21 |
| IL284210A (en) | 2021-08-31 |
| KR20210116479A (en) | 2021-09-27 |
| IL284210B2 (en) | 2025-05-01 |
| US20200197391A1 (en) | 2020-06-25 |
| JP2025037925A (en) | 2025-03-18 |
| CN113498342A (en) | 2021-10-12 |
| IL284210B1 (en) | 2025-01-01 |
| MX2021007468A (en) | 2021-08-05 |
| US20240139185A1 (en) | 2024-05-02 |
| IL317393A (en) | 2025-02-01 |
| AU2019401466B2 (en) | 2025-04-24 |
| TW202039509A (en) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106605VA (en) | Compounds that participate in cooperative binding and uses thereof | |
| EP3606492A4 (en) | Compounds that participate in cooperative binding and uses thereof | |
| EP3247378A4 (en) | Compounds that participate in cooperative binding and uses thereof | |
| SG11202001063QA (en) | Clec9a binding agents and use thereof | |
| IL298286B1 (en) | Bispecific binding proteins and uses thereof | |
| EP3247377A4 (en) | Compounds that participate in cooperative binding and uses thereof | |
| SG11202100931QA (en) | Muscle-targeting complexes and uses thereof | |
| IL272643A (en) | Binding agents | |
| IL262241A (en) | Trispecific and/or trivalent binding proteins | |
| GB201805963D0 (en) | PD-L1 Binding Affirmers and Uses Related Thereto | |
| IL263715A (en) | Lag -3 binding members | |
| IL320762A (en) | Fibroblast binding agents and use thereof | |
| EP3250609A4 (en) | Il13ra alpha 2 binding agents and use thereof in cancer treatment | |
| IL291007A (en) | Cd8 binding agents and uses thereof | |
| IL266516B (en) | Antibody binding specifically to cd66c and use thereof | |
| IL268288A (en) | Binding agents | |
| IL284053A (en) | Novel compounds and their use in therapy | |
| PT3426680T (en) | Activin type 2 receptor binding proteins and uses thereof | |
| ZA202006103B (en) | Trispecific and/or trivalent binding proteins | |
| IL277158A (en) | Compounds and uses thereof to treat tumors in a subject | |
| PL3430913T3 (en) | Composition for binding mycotoxins and its use | |
| PL3067402T3 (en) | Binder composition and use of same in wooden boards | |
| IL267565A (en) | Binding polypeptides and methods of making the same | |
| HK40060711A (en) | Compounds that participate in cooperative binding and uses thereof | |
| HK40021217A (en) | Compounds that participate in cooperative binding and uses thereof |